Skip to main content

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?

Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: 

OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LBA0005 Izokibep IL17A nanobody inhibitor 
POS0803 Vunakizumab, another IL17A inhibitor 
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.